Does antisense oligonucleotide inhibition of apolipoprotein C-III reduce plasma apoC-III and triglycerides in preclinical models and healthy subjects?
Antisense inhibition of apoC-III effectively reduces plasma triglycerides and apoC-III, supporting further clinical investigation for hypertriglyceridemia.
Antisense inhibition of apoC-III in preclinical models and in a phase I clinical trial with healthy subjects produced potent, selective reductions in plasma apoC-III and triglyceride, 2 known risk factors for cardiovascular disease. This compelling pharmacological profile supports further clinical investigations in hypertriglyceridemic subjects.
Graham et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: